Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension - PubMed (original) (raw)
Clinical Trial
Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension
K Mitsunami et al. Cardiovasc Drugs Ther. 1998 Oct.
Abstract
Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension. Ten patients (four men and six women) with essential hypertension received candesartan cilexetil 2-8 mg/day orally for 8-12 weeks. After drug administration, systolic blood pressure (BP) decreased from 178.9 +/- 17.2 mmHg (mean +/- SD) to 150.2 +/- 14.3 mmHg (P < 0.0001) and diastolic BP from 101.4 +/- 6.5 mmHg to 87.8 +/- 11.9 mmHg (P = 0.0021). Both MRI and echocardiography revealed a significant decrease in LV mass index (LVMI) after candesartan cilexetil. MRI indicated that LVMI decreased from 111.3 +/- 31.3 g/m2 to 102.6 +/- 32.1 g/m2 (P = 0.0484) and echocardiography that LVMI decreased from 123.9 +/- 31.1 g/m2 to 115.8 +/- 31.4 g/m2 (P = 0.0316). Total systemic vascular resistance decreased significantly during treatment with candesartan cilexetil in both MRI and echocardiography assessment, from 1847.2 +/- 636.3 dynes.s.cm-5 to 1540.4 +/- 432.0 dynes.s.cm-5 (P = 0.0034) on MRI and from 1820.4 +/- 318.8 dynes.s.cm-5 to 1659.0 +/- 317.7 dynes.s.cm-5 (P = 0.0060) on echocardiography. These findings suggest that candesartan cilexetil 2-8 mg/day orally for 8-12 weeks is beneficial in the regression of cardiac hypertrophy in patients with essential hypertension.
Similar articles
- Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M. Fridman K, et al. Eur J Clin Pharmacol. 1998 Sep;54(7):497-501. doi: 10.1007/s002280050503. Eur J Clin Pharmacol. 1998. PMID: 9832289 Clinical Trial. - Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K, Kahan T, Dahl M. Malmqvist K, et al. Am J Hypertens. 2000 May;13(5 Pt 1):504-11. doi: 10.1016/s0895-7061(99)00264-2. Am J Hypertens. 2000. PMID: 10826401 Clinical Trial. - Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; CATCH investigators. Cuspidi C, et al. J Hypertens. 2002 Nov;20(11):2293-300. doi: 10.1097/00004872-200211000-00030. J Hypertens. 2002. PMID: 12409969 Clinical Trial. - Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T, Arakawa K. Ogihara T, et al. J Hum Hypertens. 1999 Jan;13 Suppl 1:S27-31; discussion S33-4. doi: 10.1038/sj.jhh.1000746. J Hum Hypertens. 1999. PMID: 10076918 Review. - Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS. Sever PS. J Hypertens Suppl. 1997 Dec;15(6):S9-12. doi: 10.1097/00004872-199715066-00003. J Hypertens Suppl. 1997. PMID: 9493121 Review.
Cited by
- Diastolic heart failure: a concise review.
Aziz F, Tk LA, Enweluzo C, Dutta S, Zaeem M. Aziz F, et al. J Clin Med Res. 2013 Oct;5(5):327-34. doi: 10.4021/jocmr1532w. Epub 2013 Aug 5. J Clin Med Res. 2013. PMID: 23986796 Free PMC article. - Treatment of heart failure with normal ejection fraction.
Hamdani N, Paulus WJ. Hamdani N, et al. Curr Treat Options Cardiovasc Med. 2011 Feb;13(1):26-34. doi: 10.1007/s11936-010-0103-8. Curr Treat Options Cardiovasc Med. 2011. PMID: 21110143 Free PMC article. - Therapeutic strategies for diastolic dysfunction: a clinical perspective.
Ha JW, Oh JK. Ha JW, et al. J Cardiovasc Ultrasound. 2009 Sep;17(3):86-95. doi: 10.4250/jcu.2009.17.3.86. Epub 2009 Sep 30. J Cardiovasc Ultrasound. 2009. PMID: 20661322 Free PMC article. - Diastolic dysfunction: a link between hypertension and heart failure.
Lalande S, Johnson BD. Lalande S, et al. Drugs Today (Barc). 2008 Jul;44(7):503-13. doi: 10.1358/dot.2008.44.7.1221662. Drugs Today (Barc). 2008. PMID: 18806901 Free PMC article. Review. - Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.
Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, Nishiyama A, Takeda N. Shikata C, et al. Exp Clin Cardiol. 2007 Spring;12(1):33-6. Exp Clin Cardiol. 2007. PMID: 18650977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials